229 related articles for article (PubMed ID: 26916619)
1. RUNX1 prevents oestrogen-mediated AXIN1 suppression and β-catenin activation in ER-positive breast cancer.
Chimge NO; Little GH; Baniwal SK; Adisetiyo H; Xie Y; Zhang T; O'Laughlin A; Liu ZY; Ulrich P; Martin A; Mhawech-Fauceglia P; Ellis MJ; Tripathy D; Groshen S; Liang C; Li Z; Schones DE; Frenkel B
Nat Commun; 2016 Feb; 7():10751. PubMed ID: 26916619
[TBL] [Abstract][Full Text] [Related]
2. Relationship between RUNX1 and AXIN1 in ER-negative versus ER-positive Breast Cancer.
Chimge NO; Ahmed-Alnassar S; Frenkel B
Cell Cycle; 2017 Feb; 16(4):312-318. PubMed ID: 28055379
[TBL] [Abstract][Full Text] [Related]
3. Expression and significance of Wnt signaling components and their target genes in breast carcinoma.
He Y; Liu Z; Qiao C; Xu M; Yu J; Li G
Mol Med Rep; 2014 Jan; 9(1):137-43. PubMed ID: 24190141
[TBL] [Abstract][Full Text] [Related]
4. Redundant expression of canonical Wnt ligands in human breast cancer cell lines.
Benhaj K; Akcali KC; Ozturk M
Oncol Rep; 2006 Mar; 15(3):701-7. PubMed ID: 16465433
[TBL] [Abstract][Full Text] [Related]
5. The enigmatic role of RUNX1 in female-related cancers - current knowledge & future perspectives.
Riggio AI; Blyth K
FEBS J; 2017 Aug; 284(15):2345-2362. PubMed ID: 28304148
[TBL] [Abstract][Full Text] [Related]
6. Elevated protein expression of cyclin D1 and Fra-1 but decreased expression of c-Myc in human colorectal adenocarcinomas overexpressing beta-catenin.
Wang HL; Wang J; Xiao SY; Haydon R; Stoiber D; He TC; Bissonnette M; Hart J
Int J Cancer; 2002 Oct; 101(4):301-10. PubMed ID: 12209953
[TBL] [Abstract][Full Text] [Related]
7. Coordinated action of Axin1 and Axin2 suppresses β-catenin to regulate muscle stem cell function.
Figeac N; Zammit PS
Cell Signal; 2015 Aug; 27(8):1652-65. PubMed ID: 25866367
[TBL] [Abstract][Full Text] [Related]
8. Cyclin D1 overexpression in invasive breast cancers: correlation with cyclin-dependent kinase 4 and oestrogen receptor overexpression, and lack of correlation with mitotic activity.
Takano Y; Takenaka H; Kato Y; Masuda M; Mikami T; Saegusa M; Okayasu I
J Cancer Res Clin Oncol; 1999; 125(8-9):505-12. PubMed ID: 10480344
[TBL] [Abstract][Full Text] [Related]
9. The relationship between the insulin-like growth factor-1 system and the oestrogen metabolising enzymes in breast cancer tissue and its adjacent non-cancerous tissue.
Chong YM; Colston K; Jiang WG; Sharma AK; Mokbel K
Breast Cancer Res Treat; 2006 Oct; 99(3):275-88. PubMed ID: 16752221
[TBL] [Abstract][Full Text] [Related]
10. Regional cyclin D1 overexpression or hypoxia correlate inversely with heterogeneous oestrogen receptor-alpha expression in human breast cancer.
Kronblad A; Helczynska K; Nielsen NH; Påhlman E; Emdin S; Påhlman S; Landberg G
In Vivo; 2003; 17(4):311-8. PubMed ID: 12929585
[TBL] [Abstract][Full Text] [Related]
11. First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer.
Helms MW; Packeisen J; August C; Schittek B; Boecker W; Brandt BH; Buerger H
J Pathol; 2005 Jul; 206(3):366-76. PubMed ID: 15892165
[TBL] [Abstract][Full Text] [Related]
12. Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer.
Newman SP; Bates NP; Vernimmen D; Parker MG; Hurst HC
Oncogene; 2000 Jan; 19(4):490-7. PubMed ID: 10698518
[TBL] [Abstract][Full Text] [Related]
13. Cyclin D1 and retinoblastoma gene expression in human breast carcinoma: correlation with tumour proliferation and oestrogen receptor status.
Jares P; Rey MJ; Fernández PL; Campo E; Nadal A; Muñoz M; Mallofré C; Muntané J; Nayach I; Estapé J; Cardesa A
J Pathol; 1997 Jun; 182(2):160-6. PubMed ID: 9274525
[TBL] [Abstract][Full Text] [Related]
14. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells.
Tetsu O; McCormick F
Nature; 1999 Apr; 398(6726):422-6. PubMed ID: 10201372
[TBL] [Abstract][Full Text] [Related]
15. 5-hydroxytryptamine receptor (5-HT1DR) promotes colorectal cancer metastasis by regulating Axin1/β-catenin/MMP-7 signaling pathway.
Sui H; Xu H; Ji Q; Liu X; Zhou L; Song H; Zhou X; Xu Y; Chen Z; Cai J; Ji G; Li Q
Oncotarget; 2015 Sep; 6(28):25975-87. PubMed ID: 26214021
[TBL] [Abstract][Full Text] [Related]
16. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
17. RUNX1, a transcription factor mutated in breast cancer, controls the fate of ER-positive mammary luminal cells.
van Bragt MP; Hu X; Xie Y; Li Z
Elife; 2014 Nov; 3():e03881. PubMed ID: 25415051
[TBL] [Abstract][Full Text] [Related]
18. NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation.
Van Laere SJ; Van der Auwera I; Van den Eynden GG; van Dam P; Van Marck EA; Vermeulen PB; Dirix LY
Br J Cancer; 2007 Sep; 97(5):659-69. PubMed ID: 17700572
[TBL] [Abstract][Full Text] [Related]
19. Runx1 stabilizes the mammary epithelial cell phenotype and prevents epithelial to mesenchymal transition.
Hong D; Messier TL; Tye CE; Dobson JR; Fritz AJ; Sikora KR; Browne G; Stein JL; Lian JB; Stein GS
Oncotarget; 2017 Mar; 8(11):17610-17627. PubMed ID: 28407681
[TBL] [Abstract][Full Text] [Related]
20. AXIN1 Expression and Localization in Meningiomas and Association to Changes of APC and E-cadherin.
Pećina-Šlaus N; Kafka A; Vladušić T; Pećina HI; Hrašćan R
Anticancer Res; 2016 Sep; 36(9):4583-94. PubMed ID: 27630299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
